Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Ichiko Kinjyo"'
Publikováno v:
Regular and Young Investigator Award Abstracts.
Effector CD8+T cell interactions are critical in controlling viral infection by directly killing infected cells but overabundant or sustained activation also exacerbates tissue damage. Chemokines promote the trafficking of effector CD8+T cells into i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a13ee6103552f1668135d0b31e6fd5f
https://doi.org/10.1101/2022.09.13.507813
https://doi.org/10.1101/2022.09.13.507813
Autor:
Devin Jones, Daniel Falcon, Marina Miller, Chelsea Gregory, Ichiko Kinjyo, Eric Prossnitz, Sarah Adams
Publikováno v:
Gynecologic Oncology. 166:S118-S119
Autor:
Sarah Adams, Carolyn Muller, David O’Malley, Kari Ring, Robert Wenham, Karen Finkelstein, Teresa Rutledge, Elizabeth Lokich, Xavier Paliard, Olivier Rixe, Ichiko Kinjyo, Steven Eberhardt, Ji-Hyun Lee, Phyllis Gimotty
Publikováno v:
Gynecologic Oncology. 166:S60-S61
Autor:
Ichiko Kinjyo, Sarah F Adams
Publikováno v:
The Journal of Immunology. 208:176.15-176.15
Poly(ADP-ribose) polymerase (PARP) inhibitors have been a remarkable breakthrough in the treatment of ovarian cancers with BRCA1/2 mutations. We have previously reported that PARP-inhibition with immune checkpoint blockade extended survival of BRCA1-
Publikováno v:
Late-breaking abstracts.
Background Immunotherapy has achieved long-term survival in patients with melanoma and other tumors, introducing a new paradigm in cancer treatment. Differential outcomes among men and women receiving immune checkpoint inhibitors implicate sex steroi
Publikováno v:
Gynecologic Oncology. 159:e11-e12
Autor:
Ichiko Kinjyo, Sarah Adams
Publikováno v:
Cancer Research. 80:958-958
Background: We recently demonstrated that treatment with poly(ADP-ribose) polymerase (PARP) inhibitors sensitize BRCA1-deficient ovarian cancers to immune checkpoint blockade in preclinical models. The extended survival in response to this combinatio
Publikováno v:
Clinical Cancer Research. 26:B01-B01
Background/Objective: Despite its success in treating other tumor types, immune therapy has underperformed in ovarian cancer. One reason may be the residual effects from prior treatment. Standard therapy of ovarian cancer includes surgery and platinu
Publikováno v:
J Leukoc Biol
Infiltration of acute lymphoblastic leukemia (ALL) blasts into the CNS remains as a major clinical problem, with high risk for chemotherapy-resistant relapse and treatment-related morbidity. Despite the common inclusion of CNS prophylaxis treatments